Capillary Disease disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: CPL005 MIFTS: 45	Capillary Disease Categories: Cardiovascular diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Capillary Disease

MalaCards integrated aliases for Capillary Disease:

Name: Capillary Disease ¹² ¹⁵

Disease of Capillaries ¹² ⁷⁴

Classifications:

MalaCards categories:
Anatomical: Cardiovascular diseases

See all MalaCards categories (disease lists)

ICD10: ³⁴

Diseases of the circulatory system

Diseases of arteries, arterioles and capillaries

Diseases of capillaries

Disease of capillaries, unspecified

External Ids:

Disease Ontology ¹² DOID:1271

ICD9CM ³⁶ 448

SNOMED-CT ⁶⁹ 57223003 58729003

ICD10 ³⁴ I78 I78.9

UMLS ⁷⁴ C0155765

Sources

Summaries for Capillary Disease

Disease Ontology : ¹² A vascular disease that is located in the capillaries.

MalaCards based summary : Capillary Disease, also known as disease of capillaries, is related to hemangioendothelioma and renal pelvis carcinoma, and has symptoms including petechiae of skin An important gene associated with Capillary Disease is SLC2A1 (Solute Carrier Family 2 Member 1), and among its related pathways/superpathways are PAK Pathway and Response to elevated platelet cytosolic Ca2+. The drugs Dexamethasone acetate and Dexamethasone have been mentioned in the context of this disorder. Affiliated tissues include bone, kidney and endothelial, and related phenotypes are cellular and cardiovascular system

Sources

Related Diseases for Capillary Disease

Diseases related to Capillary Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 72)

#	Related Disease	Score	Top Affiliating Genes
1	hemangioendothelioma	10.3	KDR PECAM1
2	renal pelvis carcinoma	10.3	SLC2A1 VEGFA
3	pulmonary vein stenosis	10.3	KDR PECAM1
4	hydrocele	10.3	PECAM1 VEGFA
5	hereditary hemorrhagic telangiectasia	10.2
6	severe nonproliferative diabetic retinopathy	10.2	ALB VEGFA
7	drug-induced lupus erythematosus	10.2	KDR VEGFA
8	acroosteolysis	10.2	ALB VEGFA
9	angiomatous meningioma	10.2	KDR VEGFA
10	background diabetic retinopathy	10.2	ALB VEGFA
11	congenital lipomatous overgrowth, vascular malformations, and epidermal nevi	10.2	PECAM1 RASA1 SLC2A1
12	radiation proctitis	10.2	KDR PECAM1 VEGFA
13	hypertensive nephropathy	10.1	ALB VEGFA
14	leukostasis	10.1	KDR VEGFA
15	gastric lymphoma	10.1	ALB VEGFA
16	kidney cancer	10.1	IL2 KDR VEGFA
17	burns	10.1	ALB CSF2
18	pure red-cell aplasia	10.1	ALB IL2
19	mucositis	10.1	CSF2 IL2 VEGFA
20	clear cell renal cell carcinoma	10.1	KDR SLC2A1 VEGFA
21	arteriovenous malformations of the brain	10.1	KDR RASA1 VEGFA
22	coats disease	10.0	KDR VEGFA
23	juvenile nasopharyngeal angiofibroma	10.0	PECAM1 VEGFA
24	cryptococcal meningitis	10.0	CSF2 VEGFA
25	urinary system disease	10.0	ALB IL2 VEGFA
26	intestinal disease	10.0	ALB IL2 VEGFA
27	hydrops, lactic acidosis, and sideroblastic anemia	10.0	ALB SERPING1 VEGFA
28	gastrointestinal system disease	10.0	ALB IL2 VEGFA
29	glomeruloid hemangioma	10.0	FLT1 VEGFA
30	kaposi sarcoma	10.0	CSF2 KDR VEGFA
31	microcystic meningioma	10.0	FLT1 VEGFA
32	ovarian hyperstimulation syndrome	10.0	ALB KDR VEGFA
33	lymphangiosarcoma	10.0	IL2 PROX1 VEGFA
34	buerger disease	10.0
35	median arcuate ligament syndrome	10.0
36	systemic capillary leak syndrome	10.0
37	gastrointestinal system cancer	10.0	ALB KDR VEGFA
38	kaposiform hemangioendothelioma	10.0	KDR PECAM1 PROX1
39	endocrine gland cancer	10.0	ALB KDR VEGFA
40	lipodermatosclerosis	10.0	FLT1 VEGFA
41	capillary leak syndrome	10.0	ALB CSF2 IL2
42	cancer-associated retinopathy	10.0	FLT1 VEGFA
43	lymphangioma	10.0	KDR PROX1 VEGFA
44	acquired immunodeficiency syndrome	10.0	ALB CSF2 IL2
45	nervous system disease	9.9	ALB CSF2 VEGFA
46	placenta accreta	9.9	FLT1 KDR
47	hennekam syndrome	9.9	ALB PROX1
48	hematologic cancer	9.9	CSF2 IL2 KDR VEGFA
49	epithelioid hemangioendothelioma	9.8	FLT1 KDR VEGFA
50	corneal neovascularization	9.8	FLT1 KDR VEGFA

Graphical network of the top 20 diseases related to Capillary Disease:

Sources

Symptoms & Phenotypes for Capillary Disease

UMLS symptoms related to Capillary Disease:

petechiae of skin

MGI Mouse Phenotypes related to Capillary Disease:

⁴⁷ (show all 11)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	cellular	MP:0005384	10.18	ALB CSF2 FLT1 IL2 KDR PECAM1
2	cardiovascular system	MP:0005385	10.15	CSF2 FLT1 IL2 KDR PECAM1 PROX1
3	homeostasis/metabolism	MP:0005376	10.02	ALB CSF2 FLT1 IL2 KDR PECAM1
4	growth/size/body region	MP:0005378	10.01	CSF2 FLT1 IL2 KDR PROX1 RASA1
5	digestive/alimentary	MP:0005381	9.93	ALB IL2 PECAM1 PROX1 RASA1 VEGFA
6	immune system	MP:0005387	9.92	CSF2 FLT1 IL2 KDR PECAM1 PROX1
7	embryo	MP:0005380	9.91	CSF2 FLT1 KDR RASA1 SLC2A1 VEGFA
8	mortality/aging	MP:0010768	9.81	ALB CSF2 FLT1 IL2 KDR PROX1
9	liver/biliary system	MP:0005370	9.73	ALB IL2 KDR PECAM1 PROX1 VEGFA
10	muscle	MP:0005369	9.5	ALB FLT1 KDR PECAM1 PROX1 RASA1
11	respiratory system	MP:0005388	9.1	CSF2 IL2 KDR PECAM1 PROX1 VEGFA

Sources

Drugs & Therapeutics for Capillary Disease

Drugs for Capillary Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 300)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Dexamethasone acetate

Approved, Investigational, Vet_approved

Phase 4,Phase 3,Phase 2

1177-87-3

Dexamethasone

Approved, Investigational, Vet_approved

Phase 4,Phase 3,Phase 2

50-02-2

5743

rituximab

Approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

174722-31-7

10201696

Prednisone

Approved, Vet_approved

Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1

53-03-2

5865

Methylprednisolone

Approved, Vet_approved

Phase 4,Phase 2,Phase 3,Not Applicable

83-43-2

6741

Prednisolone phosphate

Approved, Vet_approved

Phase 4,Phase 2,Phase 3,Not Applicable

302-25-0

Methylprednisolone hemisuccinate

Approved

Phase 4,Phase 2,Phase 3,Not Applicable

2921-57-5

Prednisolone

Approved, Vet_approved

Phase 4,Phase 2,Phase 3,Not Applicable

50-24-8

5755

Clarithromycin

Approved

Phase 4,Phase 2,Phase 3

81103-11-9

84029

Amoxicillin

Approved, Vet_approved

Phase 4,Phase 2,Phase 3

26787-78-0

33613

Dexlansoprazole

Approved, Investigational

Phase 4

138530-94-6, 103577-45-3

9578005

Lansoprazole

Approved, Investigational

Phase 4

103577-45-3

3883

Angiotensin II

Approved, Investigational

Phase 4

11128-99-7, 68521-88-0, 4474-91-3

172198

Valsartan

Approved, Investigational

Phase 4

137862-53-4

60846

Bosentan

Approved, Investigational

Phase 4,Phase 2

147536-97-8

104865

Azathioprine

Approved

Phase 4,Phase 3,Not Applicable

446-86-6

2265

Vincristine

Approved, Investigational

Phase 4,Phase 2,Phase 3

2068-78-2, 57-22-7

5978

Hydroxychloroquine

Approved

Phase 4

118-42-3

3652

Bisoprolol

Approved

Phase 4

66722-44-9

2405

Captopril

Approved

Phase 4

62571-86-2

44093

Enalapril

Approved, Vet_approved

Phase 4

75847-73-3

40466924 5362032

Enalaprilat

Approved

Phase 4

76420-72-9

6917719

Eprosartan

Approved

Phase 4

133040-01-4

5281037

Perindopril

Approved

Phase 4

107133-36-8, 82834-16-0

107807

Quinapril

Approved, Investigational

Phase 4

85441-61-8

54892

Lisinopril

Approved, Investigational

Phase 4

83915-83-7, 76547-98-3

5362119

Ramipril

Approved

Phase 4

87333-19-5

5362129

Candesartan cilexetil

Approved

Phase 4

145040-37-5

2540

Cilazapril

Approved

Phase 4

88768-40-5, 92077-78-6

56330 56329

Fosinopril

Approved

Phase 4

98048-97-6

55891

Trandolapril

Approved

Phase 4

87679-37-6

5484727

Carvedilol

Approved, Investigational

Phase 4

72956-09-3

2585

Nebivolol

Approved, Investigational

Phase 4

152520-56-4, 99200-09-6, 118457-14-0

71301

Irbesartan

Approved, Investigational

Phase 4

138402-11-6

3749

Spirapril

Approved

Phase 4

83647-97-6

5311447

Losartan

Approved

Phase 4

114798-26-4

3961

Atorvastatin

Approved

Phase 4,Phase 1,Phase 2

134523-00-5

60823

Calcium

Approved, Nutraceutical

Phase 4,Phase 3,Phase 1,Not Applicable

7440-70-2

271

Caffeic acid

Experimental, Investigational

Phase 4,Phase 3

331-39-5, 501-16-6

1549111

Prednisolone hemisuccinate

Experimental

Phase 4,Phase 2,Phase 3,Not Applicable

2920-86-7

Candesartan

Experimental

Phase 4

139481-59-7

2541

Protective Agents

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1

Antineoplastic Agents, Hormonal

Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1

Hormones

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Peripheral Nervous System Agents

Phase 4,Phase 3,Phase 2,Not Applicable

Anti-Inflammatory Agents

Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1

HIV Protease Inhibitors

Phase 4,Phase 3,Phase 2

Autonomic Agents

Phase 4,Phase 3,Phase 2,Not Applicable

Gastrointestinal Agents

Phase 4,Phase 3,Phase 2,Not Applicable

glucocorticoids

Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 380)

#	Name	Status	NCT ID	Phase	Drugs
1	Caffeic Acid Combining High-dose Dexamethasone in Management of ITP	Unknown status	NCT02556814	Phase 4	Caffeic acid tablets;Dexamethasone;placebo
2	Valsartan Optimal Therapy Against Elevated Home Blood Pressure Research（VOYAGER）Study	Completed	NCT00460213	Phase 4	Valsartan 80mg daily;Valsartan 160mg daily
3	PRELIMINARY EVALUATION OF PHARMACOLOGICAL LOWERING OF AGEs	Completed	NCT02249897	Phase 4	CHOLESTYRAMINE
4	The Clinical And Subclinical Effects on Arterial Stiffness of Bosentan in Patients With Systemic Sclerosis	Completed	NCT02480335	Phase 4	bosentan
5	Reposition of Second Line Treatment in Chronic Immune Thrombocytopenia	Completed	NCT03229746	Phase 4	Hydroxychloroquine;vincristine;azathioprine
6	The Study of Different Dose Rituximab in the Treatment of ITP	Completed	NCT03258866	Phase 4	Rituximab;Rituximab
7	A Safety Study of Intravenous Immunoglobulin in Patients With Chronic Immune Thrombocytopenic Purpura (ITP)	Completed	NCT01390649	Phase 4
8	High-dose Dexamethasone Versus Conventional Dose Prednisone for Initial Treatment of Primary Immune Thrombocytopenia (ITP)	Completed	NCT01356511	Phase 4	Prednisone;Dexamethasone
9	A Longitudinal 2-year Bone Marrow Study of Eltrombopag in Previously Treated Adults, With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)	Completed	NCT01098487	Phase 4	Eltrombopag olamine
10	Study on Bone Marrow Morphology in Adults Receiving Romiplostim for Treatment of Thrombocytopenia Associated With Immune Thrombocytopenia Purpura (ITP)	Completed	NCT00907478	Phase 4
11	Platelet Function in Idiopathic Thrombocytopenic Purpura (ITP) Patients With Eltrombopag	Completed	NCT00888901	Phase 4	eltrombopag;corticosteroids (Aprednislon)
12	Helicobacter Pylori Infection in Children With Chronic Idiopathic Thrombocytopenic Purpura	Completed	NCT00467571	Phase 4	lansoprazole, clarithromycin, amoxycillin
13	NT-proBNP Selected Prevention of Cardiac Events in Diabetic Patients	Recruiting	NCT02817360	Phase 4	RAS-antagonist and beta-blocker up-to maximal dosages
14	Efficacy and Safety of rhTPO and Eltrombopag in Patients With Primary Immune Thrombocytopenia (ITP)	Recruiting	NCT03771378	Phase 4	rhTPO;eltrombopag
15	Atorvastatin in Management of Newly Diagnosed ITP	Recruiting	NCT03692754	Phase 4	Atorvastatin 20mg;Atorvastatin 10mg
16	The Efficacy and Safety of Huaiqihuang Granule in Children With Chronic Primary Immune Thrombocytopenia	Recruiting	NCT03201848	Phase 4	Placebo;Huaiqihuang Granule
17	Immunomodulation With Romiplostim in Young Adults With ITP	Recruiting	NCT02760251	Phase 4	romiplostim
18	Eval. of Potential Predictors of Disease Progression in Patients With aHUS Including Genetics, Biomarkers and Treatment	Active, not recruiting	NCT02614898	Phase 4
19	Study Assessing an Algorithm-based Strategy of Eculizumab Discontinuation in Children and Adults With aHUS	Active, not recruiting	NCT02574403	Phase 4	eculizumab
20	Study to Evaluate the Efficacy and Safety of PANZYGA in Pediatric Patients With Chronic Immune Thrombocytopenia (ITP)	Not yet recruiting	NCT03866798	Phase 4
21	Erythropoietin in Hemolytic Uremic Syndrome	Not yet recruiting	NCT03776851	Phase 4	erythropoietin
22	Effects of Helicobacter Pylori Eradication in Children With Chronic Immune Thrombocytopenic Purpura	Not yet recruiting	NCT03172676	Phase 4	Amoxicillin 50 mg/kg/day in 2 divided doses for 14 days.;Clarithromycin 15 mg/kg/day in 2 divided doses for 14 days.;Proton pump inhibitor 1 mg/kg/day in 2 divided doses 1 month
23	Different Cycles of High-dose Dexamethasone for Initial Management of Primary Immune Thrombocytopenia (ITP)	Withdrawn	NCT02642380	Phase 4	Dexamethasone (4 cycles);Dexamethasone (1 cycle)
24	Prophylactic Plasma Infusion Therapy for Congenital Thrombotic Thrombocytopenic Purpura	Withdrawn	NCT01754545	Phase 4	Octaplas infusion and placebo (group 1);Octaplas infusion and placebo (group 2)
25	DEX Combined With RTX, CSA and IVIG in the Management of Newly Diagnosed ITP Patients	Unknown status	NCT02834468	Phase 3	DEX Combined With RTX, CSA and IVIG
26	Thrombocytopenia in Gestational Period	Unknown status	NCT02751593	Phase 2, Phase 3	Dexamethasone
27	Association of FcγRIIIA Polymorphism and THPO Expression With Response to Eltrombopag in Refractory ITP Patients	Unknown status	NCT02877212	Phase 3	Eltrombopag
28	A Multicenter Study on Recombinant Human Thrombopoietin in Management of ITP in Pregnancy	Unknown status	NCT02391272	Phase 3	rhTPO
29	Recombinant Human Thrombopoietin (rhTPO) in Management of Immune Thrombocytopenia (ITP) in Pregnancy	Unknown status	NCT02270801	Phase 3	rhTPO
30	Oxidant Status and Effect of Antioxidant in Immune Thrombocytopenia	Unknown status	NCT01763658	Phase 2, Phase 3	Antox tablets(Mepaco)
31	Efficacy and Safety Study of Maintenance Treatment With rhTPO in Thrombocytopenic Subjects With ITP	Unknown status	NCT01805648	Phase 3	rhTPO
32	Sildenafil Effect on Digital Ulcer Healing in sClerodErma SEDUCE STUDY	Completed	NCT01295736	Phase 3	Sildenafil;placebo
33	Effects of Saxagliptin on Endothelial Function	Completed	NCT01319357	Phase 3	Saxagliptin;Placebo
34	Induction Therapy Study in Live Donor Kidney Transplant Recipients With a Positive Crossmatch	Completed	NCT00275509	Phase 3	Thymoglobulin;Daclizumab;Mycophenolate mofetil;Tacrolimus;Dexamethasone;Prednisone;Cytogam
35	Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) (BMT CTN 0402)	Completed	NCT00406393	Phase 3	Tacrolimus;Methotrexate;Sirolimus
36	Efficacy and Safety of Romiplostim in Adult Subjects With Persistent or Chronic Immune Thrombocytopenia (ITP)	Completed	NCT02868099	Phase 3	Romiplostim;Placebo
37	Therapy of Adults Affected by Idiopathic Thrombocytopenic Purpura With Dexamethasone	Completed	NCT02914054	Phase 2, Phase 3	High dose Dexamethasone pulses;Prednisone
38	Caffeic Acid Tablets as a Second-line Therapy for ITP	Completed	NCT02351622	Phase 3	Caffeic acid;Dexamethasone;Placebo
39	Phase III Trial With Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic Purpura	Completed	NCT02553317	Phase 3
40	An Investigation of rhTPO With Different Frequencies in the Management of ITP	Completed	NCT02139501	Phase 3	Recombinant Human Thrombopoietin (rhTPO)
41	An Open Phase 3 Study of IV-Globulin SN Inj.10% to Treat Immune Thrombocytopenia	Completed	NCT02063789	Phase 3	Human immunoglobulin intravenous
42	Daily Prednisone Versus Pulsed Dexamethasone in Treatment-naïve Adult Patients With Immune Thrombocytopenia	Completed	NCT02334813	Phase 3	Prednisone;Dexamethasone
43	Eculizumab in Shiga-toxin Related Hemolytic and Uremic Syndrome Pediatric Patients - ECULISHU	Completed	NCT02205541	Phase 3	Eculizumab;Placebo
44	A Long-term Safety Study of Eltrombopag in Pediatric Patients With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)	Completed	NCT02201290	Phase 3	Eltrombopag Tablets;Eltrombopag PfOS
45	A Efficacy and Safety Study of Fostamatinib in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)	Completed	NCT02076412	Phase 3	Fostamatinib Disodium;Placebo
46	A Efficacy and Safety Study of R935788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)	Completed	NCT02076399	Phase 3	Fostamatinib disodium;Placebo
47	Eltrombopag Phase III Study In Chinese Chronic ITP Patients	Completed	NCT01762761	Phase 3	eltrombopag;placebo
48	rhTPO Combining Dexamethasone Versus High-dose Dexamethasone for Initial Treatment of ITP	Completed	NCT01734044	Phase 3	recombinant human thrombopoietin (rhTPO); dexamethasone;Dexamethasone
49	Helicobacter Pylori Treatment in Immune Thrombocytopenic Purpura (ITP) Patients	Completed	NCT01730352	Phase 2, Phase 3	H. pylori triple therapy
50	Efficacy and Safety of Oral E5501 Plus Standard of Care for the Treatment of Thrombocytopenia in Adults With Chronic Immune Thrombocytopenia (Amendment 02)	Completed	NCT01438840	Phase 3	Avatrombopag;Placebo;Standard of care

Search NIH Clinical Center for Capillary Disease

Sources

Genetic Tests for Capillary Disease

Sources

Anatomical Context for Capillary Disease

MalaCards organs/tissues related to Capillary Disease:

⁴²

Bone, Kidney, Endothelial, Bone Marrow, Testes, Brain, B Cells

The Foundational Model of Anatomy Ontology organs/tissues related to Capillary Disease:

²⁰

The Capillaries

Sources

Publications for Capillary Disease

Articles related to Capillary Disease:

#	Title	Authors	Year
1	Growth hormone, sorbitol, and diabetic capillary disease. ( 4100908 )	Beaumont P...Williams JF	1971
2	Growth hormone, sorbitol, and diabetic capillary disease. ( 4102056 )	Gabbay KH...Kinoshita JH	1971

Sources

Genes for Capillary Disease

Genes related to Capillary Disease (0 elite genes):

(show all 12)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	SLC2A1	Solute Carrier Family 2 Member 1	Protein Coding	16.88	DISEASES inferred ¹⁵
2	PECAM1	Platelet And Endothelial Cell Adhesion Molecule 1	Protein Coding	16.6	DISEASES inferred ¹⁵
3	IL2	Interleukin 2	Protein Coding	16.54	DISEASES inferred ¹⁵
4	VEGFA	Vascular Endothelial Growth Factor A	Protein Coding	15.74	DISEASES inferred ¹⁵
5	SERPING1	Serpin Family G Member 1	Protein Coding	15.66	DISEASES inferred ¹⁵
6	KDR	Kinase Insert Domain Receptor	Protein Coding	15.43	DISEASES inferred ¹⁵
7	RASA1	RAS P21 Protein Activator 1	Protein Coding	15.3	DISEASES inferred ¹⁵
8	CSF2	Colony Stimulating Factor 2	Protein Coding	14.94	DISEASES inferred ¹⁵
9	MAP7D3	MAP7 Domain Containing 3	Protein Coding	14.89	DISEASES inferred ¹⁵
10	PROX1	Prospero Homeobox 1	Protein Coding	14.88	DISEASES inferred ¹⁵
11	FLT1	Fms Related Tyrosine Kinase 1	Protein Coding	14.84	DISEASES inferred ¹⁵
12	ALB	Albumin	Protein Coding	14.84	DISEASES inferred ¹⁵

Sources

Variations for Capillary Disease

Sources

Expression for Capillary Disease

Search GEO for disease gene expression data for Capillary Disease.

Sources

Pathways for Capillary Disease

Pathways related to Capillary Disease according to GeneCards Suite gene sharing:

(show all 28)

#	Super pathways	Score	Top Affiliating Genes
1	PAK Pathway ⁶⁵ Show member pathways Antioxidant Action of Vitamin-C ⁶⁵ Epithelial Adherens Junctions ⁶⁵	13.1	CSF2 FLT1 IL2 KDR SLC2A1
2	Response to elevated platelet cytosolic Ca2+ ⁶⁷ Show member pathways Disinhibition of SNARE formation ⁶⁷ Hemostasis ⁶⁷ Platelet activation, signaling and aggregation ⁶⁷ Platelet degranulation ⁶⁷	13.01	ALB CSF2 IL2 PECAM1 SERPING1 VEGFA
3	MAPK signaling pathway ¹ ³⁸	12.54	FLT1 KDR RASA1 VEGFA
4	Ras signaling pathway ³⁸ Show member pathways Rap1 signaling pathway ³⁸	12.5	FLT1 KDR RASA1 VEGFA
5	Immune response Fc epsilon RI pathway ²³ Show member pathways Fc epsilon RI signaling pathway ³⁸ Fc-epsilon receptor I signaling in mast cells ¹ Immune response BCR pathway ²³ VEGF signaling pathway ³⁸	12.34	CSF2 KDR RASA1 VEGFA
6	G-protein signaling RAC1 in cellular process ²³ Show member pathways CDC42 signaling events ¹ Cytoskeleton remodeling CDC42 in cellular processes ²³ RAC1 signaling pathway ¹	12.18	FLT1 IL2 KDR RASA1
7	VEGF Signaling Pathway ⁶⁸ ⁶² Show member pathways Nanoparticle-mediated activation of receptor signaling ¹ TGF-beta Signaling ⁶⁸	12.04	FLT1 KDR VEGFA
8	Fluid shear stress and atherosclerosis ³⁸	11.87	KDR PECAM1 VEGFA
9	SMAD Signaling Network ⁶⁵	11.86	FLT1 KDR VEGFA
10	EPHA forward signaling ¹ Show member pathways EPHA-mediated growth cone collapse ⁶⁷ Ephrin A reverse signaling ¹ EphrinA-EPHA pathway ¹ EphrinA-EphR Signaling ⁶⁵	11.77	KDR RASA1 VEGFA
11	S1P3 pathway ¹ Show member pathways S1P1 pathway ¹ S1P2 pathway ¹ S1P4 pathway ¹ S1P5 pathway ¹ Sphingosine 1-phosphate (S1P) pathway ¹	11.76	FLT1 KDR VEGFA
12	Embryonic and Induced Pluripotent Stem Cell Differentiation Pathways and Lineage-specific Markers ⁶⁶	11.75	ALB KDR PROX1 VEGFA
13	HIF-1 signaling pathway ³⁸	11.67	FLT1 SLC2A1 VEGFA
14	Rheumatoid arthritis ³⁸	11.61	CSF2 FLT1 VEGFA
15	Transcription_P53 signaling pathway ²³	11.5	FLT1 KDR VEGFA
16	Signaling events mediated by VEGFR1 and VEGFR2 ¹ Show member pathways VEGFR1 specific signals ¹	11.42	FLT1 KDR RASA1 VEGFA
17	Photodynamic therapy-induced NF-kB survival signaling ¹ Show member pathways Immune response MIF-mediated glucocorticoid regulation ²³	11.41	CSF2 IL2 VEGFA
18	Cell adhesion_Plasmin signaling ²³	11.27	KDR SERPING1 VEGFA
19	Angiogenesis (CST) ⁴	11.21	FLT1 KDR PECAM1 PROX1
20	Vemurafenib Pathway, Pharmacodynamics ⁶²	11.18	FLT1 KDR VEGFA
21	Syndecan-2-mediated signaling events ¹	11.15	CSF2 RASA1
22	T-Cell Receptor and Co-stimulatory Signaling ¹	11.12	IL2 RASA1
23	Cytokines and Inflammatory Response ¹	11.08	CSF2 IL2
24	Glypican 1 network ¹	11.03	FLT1 VEGFA
25	Cytoskeleton remodeling_RalB regulation pathway ²³	10.89	FLT1 KDR VEGFA
26	G-protein signaling_Rap2B regulation pathway ²³	10.83	CSF2 FLT1 IL2 KDR
27	Angiogenesis (WikiPathways) ¹	10.81	FLT1 KDR VEGFA
28	HIF-2-alpha transcription factor network ¹	10.46	FLT1 KDR SLC2A1 VEGFA

Sources

GO Terms for Capillary Disease

Cellular components related to Capillary Disease according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	extracellular region	GO:0005576	9.7	ALB CSF2 FLT1 IL2 KDR SERPING1
2	extracellular space	GO:0005615	9.5	ALB CSF2 FLT1 IL2 PECAM1 SERPING1
3	blood microparticle	GO:0072562	9.43	ALB SERPING1 SLC2A1
4	platelet alpha granule lumen	GO:0031093	8.8	ALB SERPING1 VEGFA

Biological processes related to Capillary Disease according to GeneCards Suite gene sharing:

(show all 22)

#	Name	GO ID	Score	Top Affiliating Genes
1	angiogenesis	GO:0001525	9.8	FLT1 KDR PECAM1 VEGFA
2	positive regulation of protein phosphorylation	GO:0001934	9.77	IL2 KDR VEGFA
3	positive regulation of angiogenesis	GO:0045766	9.74	FLT1 KDR VEGFA
4	regulation of cell shape	GO:0008360	9.73	KDR RASA1 VEGFA
5	positive regulation of endothelial cell proliferation	GO:0001938	9.69	KDR PROX1 VEGFA
6	vascular endothelial growth factor receptor signaling pathway	GO:0048010	9.65	FLT1 KDR VEGFA
7	negative regulation of apoptotic process	GO:0043066	9.65	ALB IL2 KDR RASA1 VEGFA
8	vasculogenesis	GO:0001570	9.63	KDR RASA1 VEGFA
9	positive regulation of cell proliferation	GO:0008284	9.63	CSF2 FLT1 IL2 KDR PROX1 VEGFA
10	platelet degranulation	GO:0002576	9.62	ALB PECAM1 SERPING1 VEGFA
11	blood vessel morphogenesis	GO:0048514	9.61	FLT1 RASA1
12	peptidyl-tyrosine phosphorylation	GO:0018108	9.59	FLT1 KDR
13	positive regulation of focal adhesion assembly	GO:0051894	9.58	KDR VEGFA
14	cell migration involved in sprouting angiogenesis	GO:0002042	9.58	KDR VEGFA
15	positive regulation of endothelial cell migration	GO:0010595	9.58	KDR PROX1 VEGFA
16	positive regulation of vascular endothelial growth factor receptor signaling pathway	GO:0030949	9.55	FLT1 VEGFA
17	monocyte differentiation	GO:0030224	9.54	CSF2 VEGFA
18	cellular response to vascular endothelial growth factor stimulus	GO:0035924	9.54	FLT1 KDR VEGFA
19	positive regulation of positive chemotaxis	GO:0050927	9.52	KDR VEGFA
20	positive regulation of endothelial cell chemotaxis by VEGF-activated vascular endothelial growth factor receptor signaling pathway	GO:0038033	9.43	KDR VEGFA
21	vascular endothelial growth factor signaling pathway	GO:0038084	9.13	FLT1 KDR VEGFA
22	positive regulation of tyrosine phosphorylation of STAT protein	GO:0042531	8.92	CSF2 IL2 PECAM1 VEGFA

Molecular functions related to Capillary Disease according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	cytokine activity	GO:0005125	9.43	CSF2 IL2 VEGFA
2	growth factor activity	GO:0008083	9.33	CSF2 IL2 VEGFA
3	protein tyrosine kinase activity	GO:0004713	8.96	FLT1 KDR
4	vascular endothelial growth factor-activated receptor activity	GO:0005021	8.62	FLT1 KDR

Sources

Sources for Capillary Disease

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ EFO

¹⁸ ExPASy

¹⁹ FDA Approved Drugs

²⁰ FMA

²¹ GeneAnalytics

²² GeneCards

²³ GeneGo (Thomson Reuters)

²⁴ GeneHancer via GeneCards

²⁵ GeneReviews

²⁶ Genetics Home Reference

²⁷ GenomeRNAi

²⁸ GEO DataSets

²⁹ GO

³⁰ GTR

³¹ HGMD

³² HMDB

³³ HPO

³⁴ ICD10

³⁵ ICD10 via Orphanet

³⁶ ICD9CM

³⁷ IUPHAR

³⁸ KEGG

³⁹ LifeMap

⁴⁰ LncRNADisease

⁴¹ LOVD

⁴² MalaCards

⁴³ MedGen

⁴⁴ MedlinePlus

⁴⁵ MeSH

⁴⁶ MESH via Orphanet

⁴⁷ MGI

⁴⁸ miR2Disease

⁴⁹ NCBI Bookshelf

⁵⁰ NCI

⁵¹ NCIt

⁵² NDF-RT

⁵³ NIH Clinical Center

⁵⁴ NIH Rare Diseases

⁵⁵ NINDS

⁵⁶ Novoseek

⁵⁷ Novus Biologicals

⁵⁸ OMIM

⁵⁹ OMIM via Orphanet

⁶⁰ Orphanet

⁶¹ PathCards

⁶² PharmGKB

⁶³ PubMed

⁶⁴ PubMed Health

⁶⁵ QIAGEN

⁶⁶ R&D Systems

⁶⁷ Reactome

⁶⁸ Sino Biological

⁶⁹ SNOMED-CT

⁷⁰ SNOMED-CT via HPO

⁷¹ SNOMED-CT via Orphanet

⁷² TGDB

⁷³ Tocris

⁷⁴ UMLS

⁷⁵ UMLS via Orphanet

⁷⁶ UniProtKB/Swiss-Prot

⁷⁷ Wikipedia